---
title: "Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: References"
description: "Reference list for the formulary evidence report on Tovecimig (CTX-009, ABL001) in Second-line advanced biliary tract cancer. 93 cited documents."
canonical: "https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references"
published: "2026-09-21T22:15:09-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: References

<a id="references"></a>

## 5 References

1. [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523268/)
2. [ASCO Daily News (2026)](https://dailynews.ascopubs.org/do/tovecimig-ctx-009-bispecific-antibody-targeting-dll4-and-vegf-a-perspectives-field)
3. [Azad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11509068/)
4. [Azad et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42920414/)
5. [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)
6. [Benson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40930144/)
7. [Boilève et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13459572/)
8. [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)
9. [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)
10. [CancerNetwork (2026)](https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-tovecimig-for-biliary-tract-cancer)
11. [Chamberlain et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8107622/)
12. [Chen et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11110281/)
13. [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)
14. [Chueh et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36575331/)
15. [ClinicalTrials.gov NCT03292783](https://clinicaltrials.gov/study/NCT03292783)
16. [ClinicalTrials.gov NCT04492033](https://clinicaltrials.gov/study/NCT04492033)
17. [ClinicalTrials.gov NCT05506943](https://clinicaltrials.gov/study/NCT05506943)
18. [ClinicalTrials.gov NCT05513742](https://clinicaltrials.gov/study/NCT05513742)
19. [ClinicalTrials.gov NCT05513742 results](https://clinicaltrials.gov/study/NCT05513742?tab=results)
20. [ClinicalTrials.gov NCT06548412](https://clinicaltrials.gov/study/NCT06548412)
21. [ClinicalTrials.gov NCT07392957](https://clinicaltrials.gov/study/NCT07392957)
22. [ClinicalTrials.gov NCT07662031](https://clinicaltrials.gov/study/NCT07662031)
23. [Compass Therapeutics 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/exh_991.htm)
24. [Compass Therapeutics COMPANION-002 data presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_992.htm)
25. [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)
26. [Compass Therapeutics COMPANION-002 survival data announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/exh_991.htm)
27. [Compass Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/exh_991.htm)
28. [Compass Therapeutics corporate update (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/exh_991.htm)
29. [Compass Therapeutics corporate update (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/exh_991.htm)
30. [Compass Therapeutics Fast Track designation announcement (2024)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/exh_991.htm)
31. [Compass Therapeutics first quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm)
32. [Compass Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm)
33. [Compass Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005295/cmpx20260630_10q.htm)
34. [Compass Therapeutics regulatory update announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm)
35. [Compass Therapeutics second quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)
36. [Compass Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007258/cmpx20260930_10q.htm)
37. [Compass Therapeutics third quarter results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm)
38. [DelveInsight (2026)](https://www.prnewswire.com/news-releases/biliary-tract-cancer-market-is-predicted-to-exhibit-remarkable-growth-at-a-cagr-of-10-1-during-the-forecast-period-20252034--delveinsight-302701327.html)
39. [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)
40. [Giuliani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41519633/)
41. [Gordon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9398147/)
42. [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)
43. [Harding et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37276871/)
44. [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)
45. [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/)
46. [Jimeno et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30229512/)
47. [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)
48. [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)
49. [Kim et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607148/)
50. [Korea Biomedical Review (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=31224)
51. [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)
52. [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)
53. [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10880349/)
54. [Lee et al. (2021)](https://doi.org/10.1158/1535-7163.TARG-21-P02-03)
55. [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11840543/)
56. [Mancarella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7370218/)
57. [Meric-Bernstam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730032/)
58. [Na et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11611764/)
59. [Nakamura et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730072/)
60. [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)
61. [NICE TA1153 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1153/chapter/3-Committee-discussion)
62. [NICE TA1153 recommendation (2026)](https://www.nice.org.uk/guidance/ta1153/chapter/1-Recommendations)
63. [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)
64. [Oh et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.540)
65. [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)
66. [Pant et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41264278/)
67. [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)
68. [Rocha-Gomes et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360021/)
69. [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)
70. [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)
71. [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)
72. [Shroff et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798714/)
73. [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)
74. [Subbiah et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32818466/)
75. [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)
76. [Van Dyke et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6467796/)
77. [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)
78. [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)
79. [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)
80. [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)
81. [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)
82. [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)
83. [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990505/)
84. [Xiao et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11894304/)
85. [Ye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9950513/)
86. [Yeom et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796106/)
87. [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)
88. [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)
89. [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)
90. [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)
91. [Zhang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826477/)
92. [Zhou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12663050/)
93. [Zhu et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461552/)

## Related pages
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Terms and abbreviations](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations.md)
- [Tovecimig (CTX-009): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/executive-summary.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Product information and disease description](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Clinical evidence](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Economic information and modeling report](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economics.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: formulary monograph](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: drug evaluation](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: prevalence by geography](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/prevalence.md)
- [Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/cost-effectiveness-analyses.md)
